Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome

doi:10.1177/1759720X14554793

Review

. 2015 Feb;7(1):26-30.

doi: 10.1177/1759720X14554793.

Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome

Ignasi Rodríguez-Pintó¹, Ricard Cervera¹, Gerard Espinosa²

Affiliations

¹ Department of Autoimmune Diseases, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain.
² Servei de Malalties Autoimmunes, Hospital Clínic, Villarroel 170, 08036-Barcelona, Catalonia, Spain.

PMID: 25649844
PMCID: PMC4314298
DOI: 10.1177/1759720X14554793

Review

Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome

Ignasi Rodríguez-Pintó et al. Ther Adv Musculoskelet Dis. 2015 Feb.

. 2015 Feb;7(1):26-30.

doi: 10.1177/1759720X14554793.

Authors

Ignasi Rodríguez-Pintó¹, Ricard Cervera¹, Gerard Espinosa²

Affiliations

¹ Department of Autoimmune Diseases, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain.
² Servei de Malalties Autoimmunes, Hospital Clínic, Villarroel 170, 08036-Barcelona, Catalonia, Spain.

PMID: 25649844
PMCID: PMC4314298
DOI: 10.1177/1759720X14554793

Abstract

The catastrophic antiphospholipid syndrome (CAPS) is characterized by thrombosis in more than three organs or systems developing over a short period of time. Despite conventional treatment with a combination of anticoagulation plus corticosteroids plus plasma exchange, and/or intravenous immunoglobulin, mortality remains high and some patients suffer from recurrent CAPS episodes. In selected patients, new therapies such as rituximab may be a treatment option. In this review, the rationale for using rituximab in CAPS is discussed.

Keywords: anti-CD20; catastrophic antiphospholipid syndrome; refractory; rituximab.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflict of interest in preparing this article.

Cited by

Catastrophic antiphospholipid syndrome treated with rituximab: A case report.
Doğru A, Ugan Y, Şahin M, Karahan N, Tunç ŞE. Doğru A, et al. Eur J Rheumatol. 2017 Jun;4(2):145-147. doi: 10.5152/eurjrheum.2017.160073. Epub 2017 Jun 1. Eur J Rheumatol. 2017. PMID: 28638691 Free PMC article.
Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas.
Lan TY, Lin YC, Tseng TC, Yang HC, Kao JH, Cheng CF, Lee TJ, Huang SC, Lu CH, Li KJ, Hsieh SC. Lan TY, et al. Gut Liver. 2023 Mar 15;17(2):288-298. doi: 10.5009/gnl210551. Epub 2022 Oct 21. Gut Liver. 2023. PMID: 36268584 Free PMC article.
Update on Antiphospholipid Syndrome: Ten Topics in 2017.
Cavazzana I, Andreoli L, Limper M, Franceschini F, Tincani A. Cavazzana I, et al. Curr Rheumatol Rep. 2018 Mar 15;20(3):15. doi: 10.1007/s11926-018-0718-4. Curr Rheumatol Rep. 2018. PMID: 29541874 Review.
Investigating the dual causative pathways linking immune cells and venous thromboembolism via Mendelian randomization analysis.
Qi N, Lyu Z, Huang L, Zhao Y, Zhang W, Zhou X, Zhang Y, Cui J. Qi N, et al. Thromb J. 2025 Jan 23;23(1):8. doi: 10.1186/s12959-025-00692-1. Thromb J. 2025. PMID: 39849535 Free PMC article.
A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome.
Vaidya B, Nakarmi S, Joshi R, Baral R. Vaidya B, et al. JNMA J Nepal Med Assoc. 2019 Mar-Apr;57(216):133-145. doi: 10.31729/jnma.4226. JNMA J Nepal Med Assoc. 2019. PMID: 31477950 Free PMC article. Review.

See all "Cited by" articles

References

1. Asherson R. (1992) The catastrophic antiphospholipid syndrome. J Rheumatol 19: 508–512. - PubMed
1. Asherson R., Cervera R., De Groot P., Erkan D., Boffa M., Piette J., et al. (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12: 530–534. - PubMed
1. Berman H., Rodríguez-Pintó I., Cervera R., Morel N., Costedoat-Chalumeau N., Erkan D., et al. (2013) Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 12: 1085–1090. - PubMed
1. Bucciarelli S., Espinosa G., Cervera R., Erkan D., Gómez-Puerta J., Ramos-Casals M., et al. (2006) Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54: 2568–2576. - PubMed
1. Buch M., Smolen J., Betteridge N., Breedveld F., Burmester G., Dörner T., et al. (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70: 909–920. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

[1] Asherson R. (1992) The catastrophic antiphospholipid syndrome. J Rheumatol 19: 508–512. - PubMed

[2] Asherson R. (1992) The catastrophic antiphospholipid syndrome. J Rheumatol 19: 508–512. - PubMed

[3] Asherson R., Cervera R., De Groot P., Erkan D., Boffa M., Piette J., et al. (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12: 530–534. - PubMed

[4] Asherson R., Cervera R., De Groot P., Erkan D., Boffa M., Piette J., et al. (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12: 530–534. - PubMed

[5] Berman H., Rodríguez-Pintó I., Cervera R., Morel N., Costedoat-Chalumeau N., Erkan D., et al. (2013) Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 12: 1085–1090. - PubMed

[6] Berman H., Rodríguez-Pintó I., Cervera R., Morel N., Costedoat-Chalumeau N., Erkan D., et al. (2013) Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 12: 1085–1090. - PubMed

[7] Bucciarelli S., Espinosa G., Cervera R., Erkan D., Gómez-Puerta J., Ramos-Casals M., et al. (2006) Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54: 2568–2576. - PubMed

[8] Bucciarelli S., Espinosa G., Cervera R., Erkan D., Gómez-Puerta J., Ramos-Casals M., et al. (2006) Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54: 2568–2576. - PubMed

[9] Buch M., Smolen J., Betteridge N., Breedveld F., Burmester G., Dörner T., et al. (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70: 909–920. - PMC - PubMed

[10] Buch M., Smolen J., Betteridge N., Breedveld F., Burmester G., Dörner T., et al. (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70: 909–920. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome

Affiliations

Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous